Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. Monoaminergic antidepressants, which are currently considered the standard of care, have several limitations, including low therapeutic response rates, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP will explore novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. Discover when newer pharmacologic agents, including neuroactive steroids and glutamatergic antidepressants are appropriate. Take away practical prescriptive considerations and apply them to real-world cases.